Parecoxib
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Parecoxib.svg | |
| Parecoxib
| |
| Systematic (IUPAC) name | |
| N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl] sulfonyl}propanamide | |
| Identifiers | |
| CAS number | |
| ATC code | M01 |
| PubChem | |
| Chemical data | |
| Formula | C19H18N2O4S |
| Mol. mass | 370.422 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Protein binding | 98% |
| Metabolism | Hepatic to valdecoxib and propionic acid CYP extensively involved (mainly CYP3A4 and 2C9) |
| Half life | 22 minutes (parecoxib) 8 hours (valdecoxib) |
| Excretion | Renal (70%, metabolites) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
Not recommended |
| Legal status | |
| Routes | Intravenous and intramuscular |
Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
